GLG News by Zocor Prescribers
-
Charles GlueckDirector of Cholesterol CenterJewish Hospital
Study: Lab test can prevent severe blood clots in testosterone patients
September 30, 2011
A recent study finds that a blood test can prevent disastrous blood clots in men receiving testosterone therapy.
-
David ZimmermanPresident/OwnerDoctors of Pharmacy, Inc.
CVS vs. Walgreen's and the latest....
June 12, 2010
As a consultant and clinical pharmacist with over 30 years experience, I am glad someone.... and in this case... Walgreen's finally woke up to fees that are insulting low and a losing proposition. It has been well established the the "average expense to dispense a prescription" (the pharmacy's actual costs including rent, payroll, overhead, etc) is in the $10 range per prescription. Why would any pharmacy sign a contract with a fee of $1.50 per prescription?
-
Ronald InnerfieldVice President of Clinical AffairsEvidence Based Medicine, Inc.
September 30, 2009
Controls to blood sugar 'cuts stroke risk' | www.barchester.com
There have been many epidemiologic studies showing a very tight correlation between baseline A1c and cardiovascular mortalityDespite this, five major randomized prospective studies have failed to show any macrovascular benefit for tighter glucose controlThe logical conclusion is that glucose is, therefore, a marker for increased mortality but not a modifiable risk factor thereofThis is why FDA has mandated cardiovascular safety for new antidiabetic agentsData dredging persists, however
-
David ZimmermanPresident/OwnerDoctors of Pharmacy, Inc.
Tamper Proof Narcotic Pain pill? YES
November 13, 2008
FDA Asks if Pain Pill Is Tamper-Proof | online.wsj.com
This drug will allow patients in severe pain to get the necessary pain relief and not have to worry about the other patients that abuse the drug.
-
Carlos DujovneAffiliate Professor of MedicineOREGON HEALTH & SCIENCE UNIVERSITY - CC
November 13, 2008
CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study | www.astrazeneca.com
1:Crestor is the most potent statin in the market,yet is 3d in sales behind Zocor and Lipitor.2:The efficacy supriority together with its capacity to lower CRP levels led to the highest rate of ASCVD prevention in the shortest period of time evr documented in statin trials.3:The trial in near 18,000 patients with otherwise lower risk of ASCVD offered $0% reduction y many ascvd endpoints.4:There were no statistical differences in side effect compared to placebo.5:The dosage was 20 mg /day (an intermediate dose below the approved max dose of 40 mg/day
-
Carlos DujovneAffiliate Professor of MedicineOREGON HEALTH & SCIENCE UNIVERSITY - CC
September 29, 2008
Many Trial Reports on FDA-Approved Drugs Go Unpublished | www.washingtonpost.com
This article is not news for clinical researchers like myself that have performed hundreds of clinical trials in collaboration with the Pharmaceutical Industry. Some of the most common reasons for that are: A)Negative studies are difficult to get published.B)Negative results for the dug of the sponsor company are of potentially damaging financial for the sponsor.C)There is no FDA regulation that prohibits a sponsor to deny access to data and freedom of publication to Investigators of the trial not employed by them. Some of the possible solutions for these problems are:A)Complete freedom of access and publication of data by investigators.B)Sponsors of studies be obligated to submit result regardless of outcome,to FDA.C)Studies shall be easily searchable in a Google style manner at FDA files,by naming a company ,a drug ,a condition,etc,etc.
-
Carlos DujovneAffiliate Professor of MedicineOREGON HEALTH & SCIENCE UNIVERSITY - CC
June 23, 2008
After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 | newsroom.lilly.com
More than 50% of patients have the 3 ccomponents to qualify for diagnosis of Metabolic Syndrome.Twwo of the components,Diabetes and Obesity are present in 20-25% of them and are difficult to control.Exenatide seems to provide that benefit.
-
Joseph BassKettering Professor & Chief Div of EndocrinologyNORTHWESTERN UNIVERSITY
Another Glinide: Where's the Beef?
March 28, 2008
Elixir Announces Completion of Enrollment in Pivotal Phase III Clinical Trial for New Diabetes Drug | www.pipelinereview.com
Elixir has turned to a strategy devoid of innovation by selecting a combination glinide (metiglinide) plus glucophage for treatment of type 2 diabetes. With the new availability of DPP4 inhibitors (sitagliptin/alogliptin) and incretin agonists (eg byetta), what is the prospect of another K channel antagonist. The old problems likely will still appear: hypoglycemia, weight gain, and possibly progression of pancreatic failure/cell death.
-
Carlos DujovneAffiliate Professor of MedicineOREGON HEALTH & SCIENCE UNIVERSITY - CC
February 19, 2008
China Plant Played Role | online.wsj.com
1:Most of our legislators are forcefully endorsing generic drug usage and importing cheaper drugs.2:As a physician specialist in Clinical Pharmacologist I am fully aware or the safety and efficacy pitfalls of poorly manufactured drugs and have done clinical research documenting the risks of patients treated with them.3:For that reason I strongly advised my patients to buy branded drugs by reputable Pharmaceutical Companies who have much to loose if found to manufacture poorly made drugs.
-
David ZimmermanPresident/OwnerDoctors of Pharmacy, Inc.
February 11, 2008
Teva wins FDA OK to sell generic Fosamax | www.reuters.com
It is important to understand the generic implications when it comes to drug product olacement on the formulary.
Leading institutions connect with members of the Healthcare councils through GLG
Most Popular Healthcare News
-
February 7, 2012
-
What do the cloud, collaboration and virtualization have in common?
January 27, 2012
-
Clinical diagnostic acquisitions dominate 2011 top ten list
January 12, 2012
-
Gene therapy success threatens drugs for hemophilia and rare diseases
December 13, 2011
-
Medtech M&A activity accelerates in 2011
November 30, 2011
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.